Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qingdao Haier Biomedical CoSHSE:688139 +1.04%84 EBITDA Margin % is 13.11% as of Mar. 2026, which is 44% below its 10-year median of 23.39. GuruFocus rates SHSE:688139 with a GF Score™ of 84/100 and a GF Value™ of ¥36.05 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Qingdao Haier Biomedical Co ranks better than 55.21% on this metric.
Qingdao Haier Biomedical Co (SHSE:688139) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qingdao Haier Biomedical Co EBITDA Margin % Related Terms
Qingdao Haier Biomedical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688139 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Qingdao Haier Biomedical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qingdao Haier Biomedical Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qingdao Haier Biomedical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qingdao Haier Biomedical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao Haier Biomedical Co (SHSE:688139) has a EBITDA Margin % of 13.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qingdao Haier Biomedical Co and its competitors. This is 44% below median its historical median of 23.39. Over the past decade, Qingdao Haier Biomedical Co's EBITDA Margin % has ranged from 9.94 to 47.73. According to the industry distribution chart, Qingdao Haier Biomedical Co ranks #365 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 44.8%.
Is Qingdao Haier Biomedical Co's EBITDA Margin % too high?
Qingdao Haier Biomedical Co's current EBITDA Margin % of 13.11% is 44% below median its 10-year median of 23.39. Over the past 10 years, this metric has ranged from a low of 9.94 to a high of 47.73. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Qingdao Haier Biomedical Co's value of 13.11% is 74.3% above this industry median. Based on the distribution chart, Qingdao Haier Biomedical Co ranks #365 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Qingdao Haier Biomedical Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qingdao Haier Biomedical Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qingdao Haier Biomedical Co ranks #365 out of 815 companies for EBITDA Margin %. This puts Qingdao Haier Biomedical Co in the upper half of its industry. The industry median EBITDA Margin % is 7.52. Qingdao Haier Biomedical Co's value of 13.11% is 74.3% above this benchmark. Historically, Qingdao Haier Biomedical Co's own EBITDA Margin % has ranged from 9.94 to 47.73 over the past decade. While the company's 10-year median is 23.39 vs. the industry median of 7.52, Qingdao Haier Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qingdao Haier Biomedical Co's current EBITDA Margin % of 13.11% is 74.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qingdao Haier Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qingdao Haier Biomedical Co's current EBITDA Margin % is 13.11%, which is 44% below median its own 10-year median of 23.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qingdao Haier Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co (SHSE:688139) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥36.05, compared to a current price of ¥28.18 — trading 21.8% below its estimated fair value. The current EBITDA Margin % is 13.11%, which is 44% below median its 10-year median of 23.39 and 74.3% above the Medical Devices & Instruments industry median of 7.52. Qingdao Haier Biomedical Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qingdao Haier Biomedical Co (SHSE:688139), the current EBITDA Margin % is 13.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qingdao Haier Biomedical Co (SHSE:688139) Overvalued in 2026?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co stock appears to be undervalued.
The current stock price of ¥28.18 is trading 21.8% below its estimated GF Value™ of ¥36.05.
GuruFocus considers Qingdao Haier Biomedical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688139:
EBITDA Margin %: 13.11% (44% below median its 10-year median of 23.39)
GF Value™: ¥36.05 vs. price of ¥28.18 (21.8% below fair value)
Industry Position: 74.3% above the Medical Devices & Instruments median (#365 of 815)
No single metric tells the full story. See the SHSE:688139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
84GF Score
Get the complete analysis for SHSE:688139
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688139 has been successfully added to your 
